Table 1. Baseline demographic and clinical characteristics of the patients.
| Characteristic | TACE (N=20) | TACE plus anlotinib (N=18) | P value |
|---|---|---|---|
| Median age (years) | 63±9.44 | 62.2±11.73 | 0.80 |
| Sex | 0.06 | ||
| Male | 18 (90.0) | 16 (88.9) | |
| Female | 2 (10.0) | 2 (11.1) | |
| NE | – | – | |
| ECOG PS | 0.83 | ||
| 0 | 10 (50.0) | 3 (16.7) | |
| 1 | 8 (40.0) | 13 (72.2) | |
| NE | 2 (10.0) | 2 (11.1) | |
| Child-Pugh | 0.59 | ||
| A | 15 (75.0) | 14 (77.8) | |
| B | 3 (15.0) | 1 (5.6) | |
| NE | 2 (10.0) | 3 (16.7) | |
| BCLC | 0.12 | ||
| B | 12 (60.0) | 13 (72.2) | |
| C | 8 (40.0) | 4 (22.2) | |
| NE | 0 (0.0) | 1 (5.6) | |
| Infection | |||
| HBV | 18 (90.0) | 18 (100.0) | |
| HCV | 0 (0.0) | 0 (0.0) | |
| Non-infected | 2 (10.0) | 0 (0.0) | |
| NE | – | – | |
| AFP (ng/mL) | 0.45 | ||
| >400 | 6 (30.0) | 4 (22.2) | |
| ≤400 | 14 (70.0) | 14 (77.8) | |
| NE | – | – | |
| Maximum lesion diameter (mm) | 80.75±36.25 | 71.42±34.57 | 0.24 |
| Number of lesions | 0.11 | ||
| Single | 10 | 9 | |
| Multiple | 10 | 7 | |
| NE | – | 2 |
Data are presented as mean ± standard deviation, n (%) or n. NE, indicators are not counted or missing; ECOG PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.